Search Results - "Hara, Hiroki"

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164 by Le, Dung T, Kim, Tae Won, Van Cutsem, Eric, Geva, Ravit, Jäger, Dirk, Hara, Hiroki, Burge, Matthew, O'Neil, Bert, Kavan, Petr, Yoshino, Takayuki, Guimbaud, Rosine, Taniguchi, Hiroya, Elez, Elena, Al-Batran, Salah-Eddin, Boland, Patrick M, Crocenzi, Todd, Atreya, Chloe E, Cui, Yi, Dai, Tong, Marinello, Patricia, Diaz, Jr, Luis A, André, Thierry

“…KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability-high/mismatch…”
Get full text

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study by Shen, Lin, Kato, Ken, Kim, Sung-Bae, Ajani, Jaffer A, Zhao, Kuaile, He, Zhiyong, Yu, Xinmin, Shu, Yongqian, Luo, Qi, Wang, Jufeng, Chen, Zhendong, Niu, Zuoxing, Zhang, Longzhen, Yi, Tienan, Sun, Jong-Mu, Chen, Jianhua, Yu, Guohua, Lin, Chen-Yuan, Hara, Hiroki, Bi, Qing, Satoh, Taroh, Pazo-Cid, Roberto, Arkenau, Hendrick-Tobias, Borg, Christophe, Lordick, Florian, Li, Liyun, Ding, Ningning, Tao, Aiyang, Shi, Jingwen, Van Cutsem, Eric

“…Patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) have poor prognosis. For these patients, treatment options are limited after…”
Get full text

Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy by Iwasa, Satoru, Kudo, Toshihiro, Takahari, Daisuke, Hara, Hiroki, Kato, Ken, Satoh, Taroh

“…After failure of first-line chemotherapy with fluoropyrimidines and platinum compounds for advanced gastric cancer, second-line chemotherapy with ramucirumab…”
Get full text

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study by Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol

“…Background The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in advanced gastric/gastroesophageal junction…”
Get full text

Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma by Sugawara, Kotaro, Fukuda, Takashi, Kishimoto, Yutaka, Oka, Daiji, Yoshii, Takako, Hara, Hiroki, Uemura, Yukari, Kawashima, Yoshiyuki, Kanda, Hiroaki, Motoi, Noriko

“…The intratumoral heterogeneity (ITH) of the tumor microenvironment (TME) has yet to be addressed in esophageal squamous cell carcinoma (ESCC). Here, we studied…”
Get full text

Survival outcomes of esophageal cancer patients with recurrence after curative treatments by Sugawara, Kotaro, Oka, Daiji, Hara, Hiroki, Yoshii, Takako, Ushijima, Hiroki, Kudo, Shigehiro, Fukuda, Takashi

“…Abstract Background Little is known about predictive factors for survival outcomes of esophageal carcinoma (EC) patients who developed recurrence after…”
Get full text

Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma by Hara, Hiroki, Tahara, Makoto, Daiko, Hiroyuki, Kato, Ken, Igaki, Hiroyasu, Kadowaki, Shigenori, Tanaka, Yoichi, Hamamoto, Yasuo, Matsushita, Hisayuki, Nagase, Michitaka, Hosoya, Yoshinori

“…The combination of docetaxel, cisplatin, and 5‐fluorouracil (DCF) as preoperative treatment for esophageal squamous cell carcinoma (ESCC) has not been…”
Get full text

A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study) by Takeuchi, Hiroya, Ito, Yoshinori, Machida, Ryunosuke, Kato, Ken, Onozawa, Masakatsu, Minashi, Keiko, Yano, Tomonori, Nakamura, Kenichi, Tsushima, Takahiro, Hara, Hiroki, Okuno, Tatsuya, Hironaka, Shuichi, Nozaki, Isao, Ura, Takashi, Chin, Keisho, Kojima, Takashi, Seki, Shiko, Sakanaka, Katsuyuki, Fukuda, Haruhiko, Kitagawa, Yuko

“…Definitive chemoradiotherapy (CRT) is the standard treatment for patients with locally advanced esophageal cancer (EC) who refuse surgery as the initial…”
Get full text

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08 by Masuishi, Toshiki, Tsuji, Akihito, Kotaka, Masahito, Nakamura, Masato, Kochi, Mitsugu, Takagane, Akinori, Shimada, Ken, Denda, Tadamichi, Segawa, Yoshihiko, Tanioka, Hiroaki, Hara, Hiroki, Sagawa, Tamotsu, Watanabe, Takanori, Takahashi, Takao, Negoro, Yuji, Manaka, Dai, Fujita, Hideto, Suto, Takeshi, Takeuchi, Masahiro, Ichikawa, Wataru, Fujii, Masashi

“…Background Regorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC). Methods This Phase 2…”
Get full text

Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G) by Nakajima, Takako Eguchi, Yamaguchi, Kensei, Boku, Narikazu, Hyodo, Ichinosuke, Mizusawa, Junki, Hara, Hiroki, Nishina, Tomohiro, Sakamoto, Takeshi, Shitara, Kohei, Shinozaki, Katsunori, Katayama, Hiroshi, Nakamura, Shinichiro, Muro, Kei, Terashima, Masanori

“…Background Oral fluoropyrimidine plus cisplatin is often not tolerated by patients with severe peritoneal metastases of gastric cancer. Combination of…”
Get full text

Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E) by Yamamoto, Shun, Kato, Ken, Daiko, Hiroyuki, Kojima, Takashi, Hara, Hiroki, Abe, Tetsuya, Tsubosa, Yasuhiro, Nagashima, Kengo, Aoki, Kazunori, Mizoguchi, Yukihiro, Kitano, Shigehisa, Yachida, Shinichi, Shiba, Satoshi, Kitagawa, Yuko

“…One of the standard treatments of resectable esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemotherapy followed by surgery. Nivolumab showed…”
Get full text

A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer by Yokota, Tomoya, Kato, Ken, Hamamoto, Yasuo, Tsubosa, Yasuhiro, Ogawa, Hirofumi, Ito, Yoshinori, Hara, Hiroki, Ura, Takashi, Kojima, Takashi, Chin, Keisho, Hironaka, Shuichi, Kii, Takayuki, Kojima, Yasushi, Akutsu, Yasunori, Matsushita, Hisayuki, Kawakami, Kentaro, Mori, Keita, Makiuchi, Takashi, Nagumo, Rie, Kitagawa, Yuko

“…Background A multicenter phase 2 trial analysed chemoselection with docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy (ICT) and…”
Get full text

Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE) by Terada, Mitsumi, Hara, Hiroki, Daiko, Hiroyuki, Mizusawa, Junki, Kadota, Tomohiro, Hori, Keisuke, Ogawa, Hirofumi, Ogata, Takashi, Sakanaka, Katsuyuki, Sakamoto, Takeshi, Kato, Ken, Kitagawa, Yuko

“…A randomized phase III trial commenced in Japan in February 2018. Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil is the current standard…”
Get full text

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma by Bando, Hideaki, Kotani, Daisuke, Tsushima, Takahiro, Hara, Hiroki, Kadowaki, Shigenori, Kato, Ken, Chin, Keisho, Yamaguchi, Kensei, Kageyama, Shun-Ichiro, Hojo, Hidehiro, Nakamura, Masaki, Tachibana, Hidenobu, Wakabayashi, Masashi, Fukutani, Miki, Togashi, Yosuke, Fuse, Nozomu, Nishikawa, Hiroyoshi, Kojima, Takashi

“…The standard treatment for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is definitive chemoradiotherapy (CRT) using…”
Get full text

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer by Kato, Ken, Doki, Yuichiro, Ura, Takashi, Hamamoto, Yasuo, Kojima, Takashi, Tsushima, Takahiro, Hironaka, Shuichi, Hara, Hiroki, Kudo, Toshihiro, Iwasa, Satoru, Muro, Kei, Yasui, Hirofumi, Minashi, Keiko, Yamaguchi, Kensei, Ohtsu, Atsushi, Kitagawa, Yuko

“…The long‐term efficacy of nivolumab in esophageal squamous cell carcinoma and its association with disease biomarkers are currently not well known. Therefore,…”
Get full text

Low voltage visible light modulation for three colors (red, green, blue) by sputtered lithium niobate thin film by Hara, Hiroki, Yoshinari, Jiro, Sasaki, Kenji, Kikukawa, Takashi, Take, Hiroshi, Mino, Tetsuya, Shimura, Atsushi, Takagi, Yasuhiro, Fukuzawa, Hideaki

“…In this study, lithium niobate (LN) optical modulator devices were fabricated using cost-effective sputtered LN thin films. We successfully achieved a…”
Get full text

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer by Doki, Yuichiro, Ueno, Makoto, Hsu, Chih‐Hung, Oh, Do‐Youn, Park, Keunchil, Yamamoto, Noboru, Ioka, Tatsuya, Hara, Hiroki, Hayama, Manabu, Nii, Masahiro, Komuro, Keiko, Sugimoto, Mariko, Tahara, Makoto

“…Background Agents targeting the programmed cell death‐1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion…”
Get full text

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial by Doi, Toshihiko, Iwasa, Satoru, Muro, Kei, Satoh, Taroh, Hironaka, Shuichi, Esaki, Taito, Nishina, Tomohiro, Hara, Hiroki, Machida, Nozomu, Komatsu, Yoshito, Shimada, Yasuhiro, Otsu, Satoshi, Shimizu, Shin, Watanabe, Morihiro

“…Background Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in several advanced cancers. We report results from…”
Get full text

Visible light modulator by sputter-deposited lithium niobate by Fukuzawa, Hideaki, Yoshinari, Jiro, Hara, Hiroki, Sasaki, Kenji, Take, Hiroshi, Yoshida, Makoto, Shimura, Atsuhi, Kikukawa, Takashi

“…Thin-film lithium niobate (LN) modulators have significant potential for ultra-high-speed optical communications. Although a significant cost reduction of the…”
Get full text

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G) by Takahashi, Naoki, Hara, Hiroki, Nagashima, Kengo, Hirata, Kenro, Masuishi, Toshiki, Matsumoto, Toshihiko, Kawakami, Hisato, Yamazaki, Kentaro, Hironaka, Shuichi, Boku, Narikazu, Muro, Kei

“…Trifluridine/tipiracil (FTD/TPI) prolongs survival in the third- or later-line treatment for advanced gastric cancer (GC), esophagogastric junction (EGJ)…”
Get full text